OSE Immunotherapeutics S.A.
OSE.PA · PAR
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | €0 | €0 | €0 | €0 |
| % Growth | 3,037.7% | -87.8% | -30.4% | – |
| Cost of Goods Sold | €0 | €0 | €0 | €0 |
| Gross Profit | €0 | €0 | €0 | €0 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | €0 | €0 | €0 | €0 |
| G&A Expenses | €0 | €0 | €0 | €0 |
| SG&A Expenses | €0 | €0 | €0 | €0 |
| Sales & Mktg Exp. | €0 | €0 | €0 | €0 |
| Other Operating Expenses | €0 | €0 | €0 | €0 |
| Operating Expenses | €0 | €0 | €0 | €0 |
| Operating Income | €0 | -€0 | -€0 | -€0 |
| % Margin | 62.6% | -1,032.2% | -101% | -63.2% |
| Other Income/Exp. Net | -€0 | -€0 | €0 | -€0 |
| Pre-Tax Income | €0 | -€0 | -€0 | -€0 |
| Tax Expense | €0 | -€0 | -€0 | -€0 |
| Net Income | €0 | -€0 | -€0 | -€0 |
| % Margin | 53.6% | -1,032.9% | -97% | -64.1% |
| EPS | 1.72 | -1.18 | -0.96 | -0.93 |
| % Growth | 245.8% | -22.9% | -3.2% | – |
| EPS Diluted | 1.72 | -1.18 | -0.96 | -0.93 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | €0 | €0 | €0 | €0 |
| Interest Expense | €0 | €0 | €0 | €0 |
| Depreciation & Amortization | €0 | €0 | €0 | €0 |
| EBITDA | €0 | -€0 | -€0 | -€0 |
| % Margin | 59% | -785.9% | -71.6% | -52.2% |